U.S. cancer survival rates have reached a significant milestone, with 70% of Americans now expected to live at least five years after a cancer diagnosis. This marks a substantial increase from the mid-1970s, when that figure stood at just 49%. The findings, released Tuesday, are based on data collected from 2015 to 2021.
Progress Across Multiple Cancers
The report details marked improvements in survival rates for several particularly challenging cancers. Five-year survival for myeloma nearly doubled, rising from 32% to 62%. Survival rates for liver cancer tripled, increasing from 7% to 22%. Late-stage lung cancer saw its five-year survival rate nearly double, moving from 20% to 37%, while melanoma and rectal cancer more than doubled their rates (from 16% to 35% and 8% to 18%, respectively).
Overall, the five-year survival rate for all cancers has more than doubled since the mid-1990s, climbing from 17% to 35%. Rebecca Siegel, senior scientific director and lead author of the report, stated that this “stunning victory” is largely attributable to decades of cancer research that has equipped clinicians with more effective treatment tools.
Challenges Remain in Equitable Access
While the overall outlook is positive, the report highlights significant disparities in cancer outcomes. American Indian and Alaska Native people currently experience the highest cancer death rates in the country, with mortality from kidney, liver, stomach, and cervical cancers roughly double that of white Americans. Black women are also more likely to die from breast and uterine cancers than non-Black women, and Black men have the highest cancer rates of any demographic group.
These disparities are linked to systemic issues, including income inequality and the lasting effects of discriminatory practices like redlining, which have disproportionately exposed marginalized communities to environmental carcinogens. Dr. René Javier Sotelo, a urologic oncologist at Keck Medicine of USC, emphasized the importance of addressing educational, cultural, and socioeconomic barriers to care, particularly in Southern California.
Dr. Sotelo noted that even in areas with robust healthcare access, like Los Angeles, gaps in awareness regarding risk factors, screening, and early warning signs persist. He cited higher rates of penile cancer among Latino men in Los Angeles as an example, attributing this not to lack of access, but to insufficient education around HPV vaccination and hygiene.
Future Outlook
Despite the encouraging trends, the report cautions that proposed federal cuts to cancer research and health insurance could jeopardize these gains. Shane Jacobson, the American Cancer Society’s chief executive, warned, “We can’t stop now.” Dr. Sotelo concurred, stating simply, “Cancer is still an issue.” It is possible that reduced funding could slow the pace of discovery and limit access to vital care. A continued focus on innovation, coupled with improved support services and policies, may be necessary to ensure that survivors have “not only more days, but better days,” as Dr. William Dahut, the American Cancer Society’s chief scientific officer, stated.
Frequently Asked Questions
What is the current five-year survival rate for all cancers?
The current five-year survival rate for all cancers is 70%, a significant increase from 49% in the mid-1970s.
Which cancers have seen the most dramatic improvements in survival rates?
Myeloma, liver cancer, late-stage lung cancer, melanoma, and rectal cancer have all experienced substantial increases in five-year survival rates, with some rates more than doubling.
What factors contribute to disparities in cancer outcomes?
The report connects disparities in survival to income inequity and the effects of past discrimination, such as redlining, which can lead to disproportionate exposure to environmental carcinogens.
As cancer survival rates continue to improve, what role do you believe community education and accessible resources will play in ensuring equitable outcomes for all?
